chartexchange

LYEL
Lyell Immunopharma, Inc. Common Stock
stockNASDAQ

At CloseNov 18, 2026 3:59:55 PM EST
13.94USD+1.939%(+0.27)116,090
After-hoursNov 18, 2026 4:00:30 PM EST
13.89USD-0.323%(-0.05)
Loading…
Loading…
444.06M
Healthcare
Biotechnology
HQ
South San Francisco, CA, USA
Previous Close
$13.67
Beta
1.80
52-Week High
$45.00 2025-12-22
52-Week Low
$7.20 2026-10-14
SMA 50
$11.01
SMA 200
$16.21
Avg. Vol 10D
270,577
Avg. Vol 30D
227,249
Avg. Vol 90D
172,538
Relative Vol
0.51
14.67M
0.4400%
140
Jun 2, 2025 · 1-for-20 (reverse)
LYEL Profile

we are entering a new era of medicine, where cancer is treated with cellular therapies: living, smart, targeted drugs. while enormous strides have been made, especially in hematologic cancers, the full promise of these therapies still lies ahead. cell-based immunotherapies have yet to show substantial benefit in solid tumors, which represent the vast majority of cancers. our goal is nothing less than to develop curative cell-based immunotherapies for any cancer, with a focus on car-ts and solid tumors.

LYEL Performance
PeriodPriceDateChangeBeta
1W15.642026-11-12-11.32%-3.181
1M8.802026-10-19+57.61%3.009
3M15.762026-08-19-11.99%2.055
6M16.132026-05-19-14.01%1.804
1Y17.222025-11-19-19.45%1.802
2Y22.202024-11-19-37.52%—
5Y216.202021-11-19-93.58%1.620
LYEL Stock Summary

Lyell Immunopharma, Inc. Common Stock (NASDAQ:LYEL) stock price today is $13.87, and today's volume is 116,090. LYEL is up 1.463% today. The 30 day average volume is 227,249. LYEL market cap is $444.06M with 32.02M shares outstanding.